利妥昔-话题@MedSci

#利妥昔#

179篇内容 | 3546人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660468, encodeId=64511660468dc, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, objectType=article, longId=168728, objectId=5792168e289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5792168e289d, replyNumber=0, likeNumber=68, createdTime=2020-05-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5792168e289d, moduleTitle=第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5792168e289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660452, encodeId=c946166045222, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：依鲁替尼联合利妥昔单抗与依鲁替尼单药治疗慢性淋巴细胞白血病的效果对比, objectType=article, longId=155412, objectId=d77e1554121e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d77e1554121e, replyNumber=0, likeNumber=77, createdTime=2019-08-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d77e1554121e, moduleTitle=Blood：依鲁替尼联合利妥昔单抗与依鲁替尼单药治疗慢性淋巴细胞白血病的效果对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d77e1554121e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660465, encodeId=aca7166046586, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性, objectType=article, longId=166325, objectId=1f1916632534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1916632534, replyNumber=0, likeNumber=152, createdTime=2019-07-08, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1916632534, moduleTitle=Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1916632534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660464, encodeId=dfba1660464b0, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效, objectType=article, longId=164439, objectId=effa16443993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=effa16443993, replyNumber=0, likeNumber=58, createdTime=2020-03-15, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=effa16443993, moduleTitle=Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=effa16443993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660455, encodeId=3773166045540, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Rheumatol：利妥昔单抗对难治性抗HMGCR免疫介导性坏死性肌病的疗效, objectType=article, longId=156013, objectId=41ba15601344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ba15601344, replyNumber=0, likeNumber=0, createdTime=2019-02-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ba15601344, moduleTitle=J Rheumatol：利妥昔单抗对难治性抗HMGCR免疫介导性坏死性肌病的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ba15601344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660440, encodeId=8c9c1660440e4, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet haemat：利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险, objectType=article, longId=142572, objectId=f2021425e29a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2021425e29a, replyNumber=0, likeNumber=109, createdTime=2018-12-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2021425e29a, moduleTitle=Lancet haemat：利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2021425e29a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660444, encodeId=bb0b1660444a7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤, objectType=article, longId=148651, objectId=82c314865156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c314865156, replyNumber=0, likeNumber=76, createdTime=2018-10-09, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c314865156, moduleTitle=NEJM：来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c314865156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660441, encodeId=50061660441ad, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Transplantation：利妥昔单抗单药且无额外脱敏治疗用于ABO血型不合活体供肝肝移植的可行性分析, objectType=article, longId=142685, objectId=48e0142685e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48e0142685e7, replyNumber=0, likeNumber=79, createdTime=2018-08-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48e0142685e7, moduleTitle=Transplantation：利妥昔单抗单药且无额外脱敏治疗用于ABO血型不合活体供肝肝移植的可行性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48e0142685e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660442, encodeId=a11c16604424f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JAMA Pediatr：维持CDNS患儿无复发生存期：利妥昔单抗vs他克莫司, objectType=article, longId=146147, objectId=597c14614eb1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597c14614eb1, replyNumber=0, likeNumber=78, createdTime=2018-09-08, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597c14614eb1, moduleTitle=JAMA Pediatr：维持CDNS患儿无复发生存期：利妥昔单抗vs他克莫司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597c14614eb1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660460, encodeId=ecbf1660460e3, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=BMJ:利妥昔单抗、阿巴西普和托利珠单抗治疗类风湿关节炎疗效差异研究, objectType=article, longId=158871, objectId=a44a1588e1a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a44a1588e1a2, replyNumber=0, likeNumber=89, createdTime=2019-04-09, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a44a1588e1a2, moduleTitle=BMJ:利妥昔单抗、阿巴西普和托利珠单抗治疗类风湿关节炎疗效差异研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a44a1588e1a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660459, encodeId=b47016604593e, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ann Rheum Dis：阿巴西普、利妥昔单抗和托珠单抗治疗类风湿性关节炎的严重感染风险, objectType=article, longId=157517, objectId=938515e517a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=938515e517a6, replyNumber=0, likeNumber=93, createdTime=2019-09-17, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=938515e517a6, moduleTitle=Ann Rheum Dis：阿巴西普、利妥昔单抗和托珠单抗治疗类风湿性关节炎的严重感染风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=938515e517a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660446, encodeId=088e16604462b, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, objectType=article, longId=149701, objectId=7340149e01c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7340149e01c4, replyNumber=0, likeNumber=82, createdTime=2019-07-24, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7340149e01c4, moduleTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7340149e01c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660445, encodeId=03e816604453a, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：利妥昔单抗预处理可降低血栓形成性血小板减少性紫癜患者的长期复发率, objectType=article, longId=148679, objectId=fdc51486e958, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdc51486e958, replyNumber=0, likeNumber=74, createdTime=2019-01-11, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdc51486e958, moduleTitle=Blood：利妥昔单抗预处理可降低血栓形成性血小板减少性紫癜患者的长期复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdc51486e958)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660450, encodeId=bbbb1660450b9, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Am J Hematol：套细胞淋巴瘤：利妥昔单抗维持治疗效果喜人, objectType=article, longId=153070, objectId=9c1a1530e044, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1a1530e044, replyNumber=0, likeNumber=85, createdTime=2019-07-07, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1a1530e044, moduleTitle=Am J Hematol：套细胞淋巴瘤：利妥昔单抗维持治疗效果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1a1530e044)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660443, encodeId=f671166044396, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：来那度胺联合利妥昔单抗作为套细胞淋巴瘤的初始治疗，缓解率高且持久, objectType=article, longId=148333, objectId=c82614833341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c82614833341, replyNumber=0, likeNumber=85, createdTime=2019-03-26, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c82614833341, moduleTitle=Blood：来那度胺联合利妥昔单抗作为套细胞淋巴瘤的初始治疗，缓解率高且持久, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c82614833341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660451, encodeId=bf4f1660451cf, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JCO：利妥昔单抗时代滤泡性淋巴瘤死亡原因：队列汇总分析, objectType=article, longId=154619, objectId=34e2154619e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34e2154619e9, replyNumber=0, likeNumber=68, createdTime=2019-10-06, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34e2154619e9, moduleTitle=JCO：利妥昔单抗时代滤泡性淋巴瘤死亡原因：队列汇总分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34e2154619e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660431, encodeId=789b166043194, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？, objectType=article, longId=130821, objectId=fe7113082182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe7113082182, replyNumber=0, likeNumber=42, createdTime=2018-06-07, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe7113082182, moduleTitle=Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe7113082182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660453, encodeId=7b9d1660453d4, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Clinical Gastro H：利妥昔单抗维持治疗可降低胰胆管免疫球蛋白G4相关疾病的复发率, objectType=article, longId=155522, objectId=21e31555224c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e31555224c, replyNumber=0, likeNumber=54, createdTime=2019-11-22, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e31555224c, moduleTitle=Clinical Gastro H：利妥昔单抗维持治疗可降低胰胆管免疫球蛋白G4相关疾病的复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e31555224c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660448, encodeId=d5d81660448ea, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=ANN ONCOL：Venetoclax联合苯达莫司汀-利妥昔单抗治疗复发/难治性非霍奇金淋巴瘤, objectType=article, longId=149945, objectId=ad0014994583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad0014994583, replyNumber=0, likeNumber=113, createdTime=2019-04-26, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad0014994583, moduleTitle=ANN ONCOL：Venetoclax联合苯达莫司汀-利妥昔单抗治疗复发/难治性非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad0014994583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660433, encodeId=7d1a16604331a, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Rheumatology（Oxford）：治疗难治性系统性红斑狼疮利妥昔单抗靠谱吗？, objectType=article, longId=134944, objectId=1e5a1349449d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e5a1349449d, replyNumber=0, likeNumber=78, createdTime=2019-03-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e5a1349449d, moduleTitle=Rheumatology（Oxford）：治疗难治性系统性红斑狼疮利妥昔单抗靠谱吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e5a1349449d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

第24届EHA大会：5F9联合利妥昔单抗治疗复发难治性非霍奇金淋巴瘤的Ib / II期临床试验

2020-05-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：依鲁替尼联合利妥昔单抗与依鲁替尼单药治疗慢性淋巴细胞白血病的效果对比

2019-08-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性

2019-07-08

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效

2020-03-15

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Rheumatol：利妥昔单抗对难治性抗HMGCR免疫介导性坏死性肌病的疗效

2019-02-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet haemat：利妥昔单抗可显著降低滤泡性淋巴瘤向侵袭性淋巴瘤转化的风险

2018-12-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：来那度胺+利妥昔单抗用于未经治疗的晚期滤泡性淋巴瘤

2018-10-09

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Transplantation：利妥昔单抗单药且无额外脱敏治疗用于ABO血型不合活体供肝肝移植的可行性分析

2018-08-19

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JAMA Pediatr：维持CDNS患儿无复发生存期：利妥昔单抗vs他克莫司

2018-09-08

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

BMJ:利妥昔单抗、阿巴西普和托利珠单抗治疗类风湿关节炎疗效差异研究

2019-04-09

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ann Rheum Dis：阿巴西普、利妥昔单抗和托珠单抗治疗类风湿性关节炎的严重感染风险

2019-09-17

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者

2019-07-24

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：利妥昔单抗预处理可降低血栓形成性血小板减少性紫癜患者的长期复发率

2019-01-11

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Am J Hematol：套细胞淋巴瘤：利妥昔单抗维持治疗效果喜人

2019-07-07

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：来那度胺联合利妥昔单抗作为套细胞淋巴瘤的初始治疗，缓解率高且持久

2019-03-26

医者仁心 (审核中...)

前往app查看评论内容

#利妥昔#

JCO：利妥昔单抗时代滤泡性淋巴瘤死亡原因：队列汇总分析

2019-10-06

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Br J Haematol：利妥昔单抗诱导治疗无症状滤泡性淋巴瘤省钱又有效？

2018-06-07

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Clinical Gastro H：利妥昔单抗维持治疗可降低胰胆管免疫球蛋白G4相关疾病的复发率

2019-11-22

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

ANN ONCOL：Venetoclax联合苯达莫司汀-利妥昔单抗治疗复发/难治性非霍奇金淋巴瘤

2019-04-26

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Rheumatology（Oxford）：治疗难治性系统性红斑狼疮利妥昔单抗靠谱吗？

2019-03-13

科室
- - 订阅+
  - 更多科室
工具
服务